Anti–TIM-3 Ab treatment resulted in improved survival (Figure 7A) and reduced leukemia burden, as assessed on day 21 after allo-HCT by luciferase imaging (Figure 7, B and C) compared with vehicle-treated mice. The gene discussed is HAVCR2; the disease is leukemia.